Profile
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 5 (2020), Article ID 5:IJCPP-148, 3 pages
https://doi.org/10.15344/2456-3501/2020/148
Case Report
Use of Long-acting Risperidone in a Patient with Schizophrenia and End Stage Renal Disease

Miguel J. Franquiz1,🆔, Renee YH Yeh2 and Ranjit Chacko3,*

1Baylor College of Medicine, Houston, Texas 77030, USA
2Texas A&M University, Department of Molecular and Cellular Medicine, Bryan, Texas 77807, USA
3Department of Psychiatry, Baylor College of Medicine, Texas A&M College of Medicine, Departments of Neurosurgery and Psychiatry, Houston Methodist Hospital, USA
Dr. Ranjit Chacko, Psychiatry and Behavioral Sciences, Baylor College of Medicine, Texas A&M College of Medicine, Departments of Neurosurgery and Psychiatry, Houston Methodist Hospital. 1 Baylor Pl, Houston, Texas 77030, METH-944, USA; E-mail: rchacko@houstonmethodist.org
22 April 2020; 16 June 2020; 18 Jun 2020
Franquiz MJ, Yeh RYH, Chacko RC (2020) Use of Long-acting Risperidone in a Patient with Schizophrenia and End Stage Renal Disease. Int J Clin Pharmacol Pharmacother 5: 148. doi: https://doi.org/10.15344/2456-3501/2020/148

References

  1. Park SC, Choi MY, Choi J, Park E, Tchoe HJ, et al. (2018) Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clin Psychopharmacol Neurosci 16: 361-375. [CrossRef] [Google Scholar] [PubMed]
  2. Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, et al. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin 30: 1643-1655. [CrossRef] [Google Scholar] [PubMed]
  3. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU, et al. (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74: 957-965. [CrossRef] [Google Scholar] [PubMed]
  4. Carney CP, Jones L, Woolson RF (2006) Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 21: 1133-1137. [CrossRef] [Google Scholar] [PubMed]
  5. Lambert TJ, Velakoulis D, Pantelis C (2003) Medical comorbidity in schizophrenia. Med J Aust 178: 67-70. [Google Scholar] [PubMed]
  6. Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, et al. (2014) Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res 14: 259-267. [CrossRef] [Google Scholar] [PubMed]
  7. Greene M, Yan T, Chang E, Hartry A, Touya M, et al. (2018) Medication compliance and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 21: 127-134. [CrossRef] [Google Scholar] [PubMed]
  8. Eerdekens M, Van Hove I, Remmerie B, Mannaert E (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91-100. [CrossRef] [Google Scholar] [PubMed]
  9. Colpaert FC (2003) Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov 2: 315-320. [CrossRef] [Google Scholar] [PubMed]
  10. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, et al. (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 114: 9-23. [CrossRef] [Google Scholar] [PubMed]
  11. Ratiopharm incorporated, Canada J7J 1P3 (1993) RISPERDAL (risperidone hydrochloride) tablets. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US).
  12. Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151. [CrossRef] [Google Scholar] [PubMed]
  13. Yasui-Furukori N, Hidestrand M, Spina E, Facciol√° G, Scordo MG, et al. (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29: 1263-1268. [Google Scholar] [PubMed]
  14. Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 (2007) RISPERDAL CONSTA (risperidone microspheres) powder for injection. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US).
  15. Hirenkumar KM, Siegel SJ (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 3: 1377-1397. [CrossRef] [Google Scholar] [PubMed]
  16. Schoretsanitis G, Spina E, Heimke C, Leon J, et al. (2017) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 10: 965-981. [CrossRef] [Google Scholar] [PubMed]
  17. Batalla A, Vera M, Torra M, Parellada E (2010) Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis. J Clin Psychopharmacol 30: 92-94. [CrossRef] [Google Scholar] [PubMed]